Opthea Limited (OPT)
| Market Cap | 310.08M |
| Revenue (ttm) | 228,254 |
| Net Income (ttm) | n/a |
| Shares Out | 42.21M |
| EPS (ttm) | -1.14 |
| PE Ratio | n/a |
| Forward PE | 6.73 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,990 |
| Open | 7.65 |
| Previous Close | 7.53 |
| Day's Range | 7.05 - 7.65 |
| 52-Week Range | 6.41 - 16.23 |
| Beta | -0.07 |
| Analysts | n/a |
| Price Target | 39.97 (+467.0%) |
| Est. Earnings Date | n/a |
About OPT
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related ...
Financial Performance
In 2020, Opthea's revenue was 87,075, a decrease of -45.26% compared to the previous year's 159,064. Losses were -16.53 million, -20.95% less than in 2019.
Financial numbers in millions AUDFinancial StatementsNews
Opthea To Present at September Investor Conferences
MELBOURNE, Australia, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal...
Opthea Reports Fiscal Year 2021 Financial Results and Corporate Highlights
Treated First Patient in Phase 3 Pivotal Trials of OPT-302 in Wet Age-Related Macular Degeneration (AMD)
Opthea Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada
MELBOURNE, Australia, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progress...
Why Opthea Stock Skyrocketed Today
The big gain appears to be a sympathy move related to positive news for another drugmaker.
Opthea Appoints Julia A. Haller, MD, and Judith Robertson to Board of Directors
MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progress...
Opthea Company Secretary Resignation
MELBOURNE, Australia, April 06, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT) advises that Mr Michael Tonroe has resigned as Company Secretary and Chief Financial Officer (CFO) of the Co...
Opthea Receives FDA Waiver for Pediatric Study Plan for OPT-302 in Wet AMD
MELBOURNE, Australia, March 31, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progres...
Opthea Treats First Patient in Phase 3 Pivotal Trials of OPT-302 in Wet AMD
MELBOURNE, Australia, March 15, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progre...
Opthea to Present at the Oppenheimer 31st Annual Healthcare Conference
MELBOURNE, Australia, March 10, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progre...
Opthea Finalizes Study Designs and Start-up Activities for Phase 3 Pivotal Clinical Trials of OPT-302 in Wet AMD
MELBOURNE, Australia, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progres...
Opthea to Present at the 10th Annual SVB Leerink Global Healthcare Conference
MELBOURNE, Australia, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progres...
Opthea Announces Pricing of Initial Public Offering in the United States
MELBOURNE, Australia, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progres...
Opthea IPO: What Investors Should Know About The Genentech, Regeneron Challenger
Opthea, an Australian clinical stage biotech company, is going public to help fund its Phase 3 trials and take on two large biotech companies. About Opthea: The main area of focus for Opthea Ltd (NASDAQ...
Opthea Readies Plan For U.S. IPO
Opthea has filed proposed terms to raise capital from a U.S. IPO.